schizophrenia

Karuna keeps $6B sales forecast alive with blood pressure data on schizophrenia drug
Karuna keeps $6B sales forecast alive with blood pressure data on schizophrenia drug
Fierce Biotech
Karuna Therapeutics
KarXT
blood pressure
schizophrenia
Flag link:
Reviva Pharmaceuticals reports data from schizophrenia drug trial
Reviva Pharmaceuticals reports data from schizophrenia drug trial
Clinical Trials Arena
Reviva
brilaroxazine
clinical trials
schizophrenia
Flag link:
A brain-focused biotech raises $225M to develop drugs for schizophrenia, Parkinson’s
A brain-focused biotech raises $225M to develop drugs for schizophrenia, Parkinson’s
BioPharma Dive
Maplight Therapeutics
funding
schizophrenia
Flag link:
Reviva Pharma's schizophrenia drug succeeds in late-stage study
Reviva Pharma's schizophrenia drug succeeds in late-stage study
Reuters
Reviva
schizophrenia
clinical trials
brilaroxazine
Flag link:
Newron's Schizophrenia Candidate Scores Mid-Stage Win, Moves to Phase III
Newron's Schizophrenia Candidate Scores Mid-Stage Win, Moves to Phase III
BioSpace
Newron Pharma
clinical trials
evenamide
schizophrenia
Flag link:
Karuna submits schizophrenia drug for US approval
Karuna submits schizophrenia drug for US approval
BioPharma Dive
Karuna Therapeutics
KarXT
schizophrenia
FDA
Flag link:
Gilead-backed Lyndra Therapeutics cuts nearly a quarter of staff as ph. 3 data nears
Gilead-backed Lyndra Therapeutics cuts nearly a quarter of staff as ph. 3 data nears
Fierce Pharma
Lyndra Therapeutics
layoffs
schizophrenia
Risperidone
Flag link:
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Flag link:
Sumitomo, Otsuka’s Schizophrenia Candidate Fails Phase III Trials
Sumitomo, Otsuka’s Schizophrenia Candidate Fails Phase III Trials
BioSpace
Sumitomo Pharma
Otsuka
clinical trials
ulotaront
schizophrenia
Flag link:
Roche Terminates Second Phase II Schizophrenia Trial
Roche Terminates Second Phase II Schizophrenia Trial
BioSpace
Roche
schizophrenia
ralmitaront
clinical trials
Flag link:
J&J beats back Viatris' generic challenge to schizophrenia med Invega Trinza
J&J beats back Viatris' generic challenge to schizophrenia med Invega Trinza
Fierce Pharma
JNJ
schizophrenia
generics
Trinza
Viatris
Flag link:
Teva, MedinCell win FDA approval for slow-release schizophrenia drug Uzedy
Teva, MedinCell win FDA approval for slow-release schizophrenia drug Uzedy
Fierce Pharma
Teva Pharmaceutical
MedinCell
FDA
schizophrenia
Uzedy
Risperidone
Flag link:
Schizophrenia: Four major clinical trials to watch in 2023
Schizophrenia: Four major clinical trials to watch in 2023
Clinical Trials Arena
clinical trials
schizophrenia
Reviva
brilaroxazine
Newron
evenamide
Sunovion
ulotaront
Acadia Pharma
pimavanserin
Flag link:
Royalty Pharma hands off $100M upfront for PureTech royalty on Karuna's schizophrenia hopeful
Royalty Pharma hands off $100M upfront for PureTech royalty on Karuna's schizophrenia hopeful
Endpoints
Royalty Pharma
Karuna Therapeutics
KarXT
schizophrenia
PureTech
Flag link:
Karuna’s schizophrenia drug succeeds in a second late-stage trial
Karuna’s schizophrenia drug succeeds in a second late-stage trial
BioPharma Dive
Karuna
clinical trials
schizophrenia
KarXT
Flag link:
Newron’s Schizophrenia Candidate Gets Better Over Time
Newron’s Schizophrenia Candidate Gets Better Over Time
BioSpace
Newron Pharma
schizophrenia
evenamide
Flag link:
Following in Lilly's footsteps, Teva takes 2nd long-acting schizophrenia drug into phase 3
Following in Lilly's footsteps, Teva takes 2nd long-acting schizophrenia drug into phase 3
Fierce Pharma
Teva Pharmaceutical
clinical trials
schizophrenia
Eli Lilly
antipsychotics
Olanzapine
TV-44749
Flag link:
Luye claims its first FDA approval, for bi-weekly schizophrenia drug
Luye claims its first FDA approval, for bi-weekly schizophrenia drug
Pharmaphorum
Luye Pharma
China
FDA
schizophrenia
Rykindo
Flag link:
JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate
JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate
Fierce Biotech
JPMHC 2023
Karuna Therapeutics
drug launches
schizophrenia
KarXT
Flag link:
Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch
Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch
Fierce Biotech
Karuna Therapeutics
schizophrenia
KarXT
drug launches
Flag link:

Pages